HPV Associated Head and Neck Cancer

Cancers - Tập 8 Số 8 - Trang 75
Tara Spence1, Jeff Bruce2, Kenneth W. Yip3, Fei‐Fei Liu4,5,6
1Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. [email protected].
2Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. [email protected].
3Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. [email protected].
4Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada. [email protected].
5Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. [email protected].
6Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada. [email protected].

Tóm tắt

Head and neck cancers (HNCs) are a highly heterogeneous group of tumours that are associated with diverse clinical outcomes. Recent evidence has demonstrated that human papillomavirus (HPV) is involved in up to 25% of HNCs; particularly in the oropharyngeal carcinoma (OPC) subtype where it can account for up to 60% of such cases. HPVs are double-stranded DNA viruses that infect epithelial cells; numerous HPV subtypes, including 16, 18, 31, 33, and 35, drive epithelial cell transformation and tumourigenesis. HPV positive (HPV+) HNC represents a distinct molecular and clinical entity from HPV negative (HPV−) disease; the biological basis for which remains to be fully elucidated. HPV positivity is strongly correlated with a significantly superior outcome; indicating that such tumours should have a distinct management approach. This review focuses on the recent scientific and clinical investigation of HPV+ HNC. In particular, we discuss the importance of molecular and clinical evidence for defining the role of HPV in HNC, and the clinical impact of HPV status as a biomarker for HNC.

Từ khóa


Tài liệu tham khảo

Jemal, 2011, Global cancer statistics, CA Cancer J. Clin., 61, 69, 10.3322/caac.20107

Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J. Clin. Oncol., 24, 2137, 10.1200/JCO.2005.05.2308

Mashberg, 1993, Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans, Cancer, 72, 1369, 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L

The Nobel Prize in Physiology or Medicine 2008. Available online: http://nobelprize.org/nobel_prizes/medicine/laureates/2008/press.html.

Syrjanen, 1983, Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions, Br. J. Oral Surg., 21, 147, 10.1016/0007-117X(83)90060-4

IARC (1995). Human Papillomaviruses. IARC Monogr. Eval. Carcinog. Risks Hum., 64, 1–428.

Pytynia, 2014, Epidemiology of HPV-associated oropharyngeal cancer, Oral Oncol., 50, 380, 10.1016/j.oraloncology.2013.12.019

Chaturvedi, 2011, Human papillomavirus and rising oropharyngeal cancer incidence in the United States, J. Clin. Oncol., 29, 4294, 10.1200/JCO.2011.36.4596

Cancer Genome Atlas Network (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517, 576–582.

Shi, 2009, Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma, J. Clin. Oncol., 27, 6213, 10.1200/JCO.2009.23.1670

Huang, 2013, Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis, J. Clin. Oncol., 31, 543, 10.1200/JCO.2012.44.0164

NIAID Papillomavirus Episteme Kowledge Source: HPV16, Available online: http://pave.niaid.nih.gov/.

Suzich, 1995, Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas, Proc. Natl. Acad. Sci. USA, 92, 11553, 10.1073/pnas.92.25.11553

Bratman, 2016, Human papillomavirus genotype association with survival in head and neck squamous cell carcinoma, JAMA Oncol., 2, 823, 10.1001/jamaoncol.2015.6587

Ndiaye, 2014, HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis, Lancet. Oncol., 15, 1319, 10.1016/S1470-2045(14)70471-1

Anderson, 2016, HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland, J. Med. Virol., 88, 1262, 10.1002/jmv.24447

Goodman, 2015, Human papillomavirus genotype and oropharynx cancer survival in the United States of America, Eur. J. Cancer, 51, 2759, 10.1016/j.ejca.2015.09.005

Hebner, 2006, Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity, Rev. Med. Virol., 16, 83, 10.1002/rmv.488

Moody, 2010, Human papillomavirus oncoproteins: Pathways to transformation, Nat. Rev. Cancer, 10, 550, 10.1038/nrc2886

Duensing, 2000, The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle, Proc. Natl. Acad. Sci. USA, 97, 10002, 10.1073/pnas.170093297

DiMaio, 2001, Mechanisms of cell transformation by papillomavirus E5 proteins, Oncogene, 20, 7866, 10.1038/sj.onc.1204915

Scheffner, 1990, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8

Munger, 1989, Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product, EMBO J., 8, 4099, 10.1002/j.1460-2075.1989.tb08594.x

Song, 2000, Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis, Virology, 267, 141, 10.1006/viro.1999.0106

DiMaio, 2013, The E5 proteins, Virology, 445, 99, 10.1016/j.virol.2013.05.006

Goon, P.K., Stanley, M.A., Ebmeyer, J., Steinstrasser, L., Upile, T., Jerjes, W., Bernal-Sprekelsen, M., Gorner, M., and Sudhoff, H.H. (2009). HPV & head and neck cancer: A descriptive update. Head Neck Oncol.

Chaturvedi, 2008, Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States, J. Clin. Oncol., 26, 612, 10.1200/JCO.2007.14.1713

Sturgis, 2007, Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancers?, Cancer, 110, 1429, 10.1002/cncr.22963

Rischin, 2010, Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial, J. Clin. Oncol., 28, 4142, 10.1200/JCO.2010.29.2904

Gillison, 2000, Evidence for a causal association between human papillomavirus and a subset of head and neck cancers, J. Natl. Cancer Inst., 92, 709, 10.1093/jnci/92.9.709

Fakhry, 2008, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial, J. Natl. Cancer Inst., 100, 261, 10.1093/jnci/djn011

Posner, 2011, Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial, Ann. Oncol., 22, 1071, 10.1093/annonc/mdr006

Ellison, 2012, Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis, Oral Oncol., 48, 1191, 10.1016/j.oraloncology.2012.06.019

Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N. Engl. J. Med., 363, 24, 10.1056/NEJMoa0912217

Huang, 2013, Temporal nodal regression and regional control after primary radiation therapy for N2–N3 head-and-neck cancer stratified by HPV status, Int. J. Radiat. Oncol. Biol. Phys., 87, 1078, 10.1016/j.ijrobp.2013.08.049

Huang, 2015, Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas, J. Clin. Oncol., 33, 836, 10.1200/JCO.2014.58.6412

Smith, E.M., Rubenstein, L.M., Haugen, T.H., Pawlita, M., and Turek, L.P. (2012). Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: A case for multifactor disease. J. Oncol.

Huang, 2012, Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation, Radiother. Oncol., 103, 49, 10.1016/j.radonc.2012.02.009

Parfenov, 2014, Characterization of HPV and host genome interactions in primary head and neck cancers, Proc. Natl. Acad. Sci. USA, 111, 15544, 10.1073/pnas.1416074111

Sepiashvili, 2015, Novel insights into head and neck cancer using next-generation “omic” technologies, Cancer Res., 75, 480, 10.1158/0008-5472.CAN-14-3124

Walter, V., Yin, X., Wilkerson, M.D., Cabanski, C.R., Zhao, N., Du, Y., Ang, M.K., Hayward, M.C., Salazar, A.H., and Hoadley, K.A. (2013). Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS ONE, 8.

Lechner, M., Frampton, G.M., Fenton, T., Feber, A., Palmer, G., Jay, A., Pillay, N., Forster, M., Cronin, M.T., and Lipson, D. (2013). Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV− tumors. Genome Med.

Stransky, 2011, The mutational landscape of head and neck squamous cell carcinoma, Science, 333, 1157, 10.1126/science.1208130

Korzeniewski, 2011, Genomic instability and cancer: Lessons learned from human papillomaviruses, Cancer Lett., 305, 113, 10.1016/j.canlet.2010.10.013

Seethala, R.R., Weinreb, I., Carlson, D.L., McHugh, J.B., Harrison, L.B., Richardson, M.S., Sahah, J., Ferris, R.L., Wenig, B.M., and Thompson, L.D.R. Protocol for the examination of specimens from patients with carcinomas of the larynx. Available online: http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/larynx-13protocol-3300.pdf.

Westra, 2014, Detection of human papillomavirus (HPV) in clinical samples: Evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas, Oral Oncol., 50, 771, 10.1016/j.oraloncology.2014.05.004

Kosel, 2007, Increased levels of HPV16 E6*I transcripts in high-grade cervical cytology and histology (CIN II+) detected by rapid real-time RT-PCR amplification, Cytopathology, 18, 290, 10.1111/j.1365-2303.2007.00481.x

Giuliani, 2006, Comparison of DNA sequencing and Roche Linear array in human papillomavirus (HPV) genotyping, Anticancer Res., 26, 3939

Bartel, 2004, MicroRNAs: Genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5

Xue, 2013, Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: A comprehensive meta-analysis of studies conducted between 1979 and 2011, Am. J. Epidemiol., 178, 325, 10.1093/aje/kws479

Bertoli, 2015, MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer, Theranostics, 5, 1122, 10.7150/thno.11543

He, 2015, Current state of circulating microRNAs as cancer biomarkers, Clin. Chem., 61, 1138, 10.1373/clinchem.2015.241190

Hui, 2013, Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma, Clin. Cancer Res., 19, 2154, 10.1158/1078-0432.CCR-12-3572

Childs, 2009, Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma, Am. J. Pathol., 174, 736, 10.2353/ajpath.2009.080731

Gee, 2010, hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer, Cancer, 116, 2148, 10.1002/cncr.25009

Spence, T., Bruce, J., Yip, K.W., and Liu, F.F. (2016). MicroRNAs in nasopharyngeal carcinoma. Chin. Clin. Oncol.

Tinhofer, 2014, Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck, Ann. Oncol., 25, 2042, 10.1093/annonc/mdu271

Huang, 2013, Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer, Oral Oncol., 49, 79, 10.1016/j.oraloncology.2012.07.015

Huang, 2015, Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status, Cancer, 121, 545, 10.1002/cncr.29100

Wansom, 2010, Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer, Arch. Otolaryngol. Head Neck Surg., 136, 1267, 10.1001/archoto.2010.211

Cao, 2012, Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients, Int. J. Radiat. Oncol. Biol. Phys., 82, e351, 10.1016/j.ijrobp.2011.05.061

Kimple, 2013, Enhanced radiation sensitivity in HPV-positive head and neck cancer, Cancer Res., 73, 4791, 10.1158/0008-5472.CAN-13-0587

Dok, 2014, p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors, Cancer Res., 74, 1739, 10.1158/0008-5472.CAN-13-2479

Overgaard, 2005, Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial, Lancet. Oncol., 6, 757, 10.1016/S1470-2045(05)70292-8

Mortensen, 2012, FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial, Radiother. Oncol., 105, 14, 10.1016/j.radonc.2012.09.015

Sorensen, 2013, Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells, Radiother. Oncol., 108, 500, 10.1016/j.radonc.2013.06.011

Marur, 2010, HPV-associated head and neck cancer: A virus-related cancer epidemic, Lancet Oncol., 11, 781, 10.1016/S1470-2045(10)70017-6

Heusinkveld, 2012, Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer, Int. J. Cancer, 131, E74, 10.1002/ijc.26497

Ward, 2014, Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer, Br. J. Cancer, 110, 489, 10.1038/bjc.2013.639

Hoffmann, 2006, T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx, Int. J. Cancer, 118, 1984, 10.1002/ijc.21565

Albers, 2005, Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck, Cancer Res., 65, 11146, 10.1158/0008-5472.CAN-05-0772

Deboni, 2012, Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer, Support. Care Cancer, 20, 2903, 10.1007/s00520-012-1418-7

Corry, 2010, Optimising the therapeutic ratio in head and neck cancer, Lancet. Oncol., 11, 287, 10.1016/S1470-2045(09)70384-5

Chera, 2015, Phase 2 Trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, Int. J. Radiat. Oncol. Biol. Phys., 93, 976, 10.1016/j.ijrobp.2015.08.033

Marur, S., Li, S., Cmelak, A., Gillison, M., Ferris, R.L., Bauman, J., Zhao, W., W., W., Chung, C.H., and Wagner, L. (2013). E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). J. Clin. Oncol., 31, abstr 6005.

Thông tin
Thông tin xuất bản

Cancers

Tập 8 Số 8

75

Thông tin tác giả